Maxposure (MAXPOSURE)

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 46.33% shows strong demand or expansion.
• ROCE of 16.30% indicates capital is being deployed at a reasonable return.
• Piotroski F-Score of 7/9 suggests overall financial health is above average.
• Promoter holding of 61.56% aligns management interests with minority shareholders.
• Trailing P/E of 9.68 provides a low entry multiple if earnings stabilise.

Concerns

• Profit growth of just 1.19% despite 46.33% sales growth implies margin compression or rising costs.
• No dividend means shareholders rely entirely on capital appreciation.
• Book value and debt/equity are unavailable, leaving balance-sheet risk unquantified.
• Media & entertainment is competitive, and the 52-week swing from ₹31.05 to ₹64.00 indicates speculative volatility.

AI Analysis

When I first glance at Maxposure, I see a small-cap media and entertainment company priced at ₹40 with a market capitalisation of ₹83 crore and a trailing P/E of 9.68. That looks like a cheap stock. But cheapness alone is never enough. The Return on Capital Employed of 16.30% is a positive signal, as is a Piotroski F-Score of 7 out of 9, which hints at decent financial health. Promoter holding of 61.56% also tells me the owners are aligned with public shareholders. Those are real strengths. However, I need to understand the economics of the business. The latest quarter shows sales of ₹45 crore and net profit of ₹5 crore. Sales grew 46.33%, yet profit growth was only 1.19%. That is a serious disconnect. For a value investor, revenue without earnings is just a story. It suggests the company is spending heavily to win business, margins are under pressure, or costs are rising faster than pricing power. The media and entertainment industry is competitive, with limited durable competitive advantages, so I cannot assume these returns will last. There is zero dividend, and the 52-week range of ₹31.05 to ₹64.00 shows how volatile this stock can be. Without book value or debt/equity data, I cannot calculate a balance-sheet margin of safety with confidence. The PEG ratio of 0.28 appears attractive, but it must be based on a profit growth rate I do not currently see in the numbers. As Graham taught, you pay for quality and growth only when they are supportable. At ₹40, Maxposure may be a fair business at a cheap price, but I need evidence that profit growth can catch up with sales growth. Until then, I would watch it from the sidelines rather than bet the farm.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer